<DOC>
	<DOCNO>NCT02629419</DOCNO>
	<brief_summary>This open-label , dose-titration trial study efficacy , safety , pharmacokinetics oral cochleate amphotericin B ( CAMB ) treatment mucocutaneous candidiasis infection patient refractory intolerant standard non intravenous therapy .</brief_summary>
	<brief_title>CAMB/MAT2203 Patients With Mucocutaneous Candidiasis</brief_title>
	<detailed_description>Patients age 18 75 year mucocutaneous candidiasis ( esophageal , oropharyngeal , vulvovaginal ) refractory intolerant standard non-intravenous therapy enrol . Patients initially treat short-term dose titration period , dose may increase patient respond clinically . Patients respond clinically high dose drug discontinue protocol . Patients respond treatment tolerate study medication eligible enter long-term extension ( 6-months ) .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Chronic Mucocutaneous</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Patients must clinical diagnosis least one following : Persistent OPC great 2 week document least one occasion KOH fungal stain confirm mycological culture azole resistant within previous 6 month and/or intolerance standard non intravenous therapy . EC associate clinical symptom retrosternal pain , odynophagia , and/or pain swallow document esophageal biopsy visualization culture document azole resistance within previous 6 month and/or intolerance standard nonintravenous therapy . Persistent VVC great 2 week document presence vaginal symptom positive wet mount show Candida structure confirm vaginal culture positive Candida azole resistance within previous 6 month and/or intolerance standard non intravenous therapy . Patient expect survive &gt; = 6 month . Willing sample store future research . Agree use highly effective contraception . Contraception : Because effect CAMB develop human fetus unknown , sexually active patient childbearing potential must agree use highly effective contraception outline study entry duration study participation . Females childbearing potential must negative pregnancy test result receive CAMB . During course study , patient becomes pregnant suspect pregnant , inform study staff primary care physician immediately . Acceptable form contraception : Intrauterine device ( IUD ) equivalent . Hormonal contraceptive ( eg , consistent , timely continuous use contraceptive pill , patch , ring , implant , injection reach full efficacy prior dose ) . If patient us contraceptive pill , patch , ring , barrier method ( eg , male/female condom , cap , diaphragm plus spermicide ) must also used time potentially reproductive sexual activity . Be stable , longterm monogamous relationship , per PI assessment , partner pose potential pregnancy risk , eg , undergone vasectomy least 6 month prior first dose study agent sex patient . Have hysterectomy and/or bilateral tubal ligation ovary remove . Allergy AMB product component CAMB ( eg , phosphatidylserine ) Have evidence systemic fungal infection require intravenous antifungal therapy Pregnant nursing woman , woman intend become pregnant study period Had concomitant medical condition could interfere study drug evaluation contraindication propose investigational treatment base upon know agent safety profile toxicity . Had follow laboratory abnormality screen visit : Alanine Transaminase ( ALT ) , Aspartate Transaminase ( AST ) Alkaline phosphatase ( ALP ) &gt; 2.5 time upper limit normal ( ULN ) . Total bilirubin level &gt; 2.5 time ULN Serum creatinine level &gt; 2 time ULN Absolute neutrophil count less 500 cells/microliter Potassium level less equal 3.5 mmol/L Exposure investigational agent within 4 week prior Day 0 ( Baseline ) . Current recent history ( past 12 month ) drug alcohol abuse . Use intravenous AMB product within 1week start study drug administration Use nonintravenous AMB product ( oral AMB swish ) within 72 hour prior start study drug administration Subjects receive potassium supplement . Any condition investigator believe would interfere patient ability provide inform consent , comply study instruction , might confound interpretation study result put subject undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>STAT3 deficient Hyper IgE syndrome</keyword>
	<keyword>Gain function STAT1 defect</keyword>
	<keyword>Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy ( APECED )</keyword>
	<keyword>IL-17/IL-22 autoantibody thymoma</keyword>
	<keyword>Job 's Syndrome ( Hyperimmunoglobulin E Syndrome , Buckley Syndrome )</keyword>
</DOC>